Objective. To investigate the relationship between blood platelet-to-lymphocyte ratio (PLR) and clinicopathological characteristics of patients with advanced non-small cell lung cancer (NSCLC) and evaluate the value of PLR for predicting the efficacy of chemotherapy and prognosis. Methods. The clinical data of 175 patients with advanced NSCLC diagnosed from March 2017 to December 2018 in our hospital were retrospectively analyzed, and the data of 175 healthy subjects from our hospital physical examinations were included. The platelet was detected by using a blood cell analyzer to calculate PLR. According to the average PLR value (197) before chemotherapy, 175 patients were divided into the low PLR group (=78) and the high PLR group (=97). The relationship between the expression levels of PLR and clinicopathologic features was analyzed, and the Kaplan–Meier survival curve was used to analyze the relationship between the expression levels of PLR and prognosis. Results. The results showed that prechemotherapy PLR levels were significantly higher in NSCLC compared with the healthy subjects (). After 4 cycles of chemotherapy, the PLR levels were significantly lower than those during prechemotherapy (). The proportion of TNM (IV) stage cases in the low PLR group was lower than that in the high PLR group (). The total effective rate of the first-line chemotherapy was 46.9% (82/175). The effective rate of IIIb staging was higher than that in IV staging (), and the effective rate of the low PLR group was higher than that in the high PLR group (). Multivariate logistic analysis showed that TNM stage 4 and high PLR level were the independent risk factors for the efficacy of the first-line chemotherapy in patients with advanced NSCLC (), and the high PLR level was an independent risk factor affecting the prognosis of patients with advanced NSCLC. The median overall survival (OS) of patients with the low PLR group was 20.8 months, higher than the 12.0 months of patients with the high PLR group (). Conclusion. PLR might have a certain clinical significance for predicting the TNM staging of NSCLC and can provide important diagnostic and prognostic results for patients.

中文翻译：

---

PLR与晚期NSCLC患者临床病理特征的关系及其对化疗疗效和预后的预测价值

客观的。探讨血小板与淋巴细胞比值（PLR）与晚期非小细胞肺癌（NSCLC）患者临床病理特征的关系，评价PLR对化疗疗效及预后的预测价值。方法。回顾性分析我院2017年3月至2018年12月确诊的175例晚期NSCLC患者的临床资料，并纳入我院体检的175例健康受试者数据。使用血细胞分析仪检测血小板并计算PLR。根据化疗前平均PLR值（197），将175例患者分为低PLR组（=78）和高PLR组（=97）。分析PLR表达水平与临床病理特征的关系，并采用Kaplan-Meier生存曲线分析PLR表达水平与预后的关系。结果。结果显示，与健康受试者相比，NSCLC 患者化疗前 PLR 水平显着升高（）。4个周期化疗后，PLR水平显着低于化疗前（）。低PLR组TNM（IV）期病例比例低于高PLR组（）。一线化疗总有效率46.9%（82/175）。IIIb分期的有效率高于IV分期（），且低PLR组有效率高于高PLR组（）。多因素logistic分析显示TNM分期4期和高PLR水平是晚期NSCLC患者一线化疗疗效的独立危险因素。),且高PLR水平是影响晚期NSCLC患者预后的独立危险因素。低PLR组患者的中位总生存期（OS）为20.8个月，高于高PLR组患者的12.0个月（）。 结论。PLR对于预测NSCLC的TNM分期可能具有一定的临床意义，可以为患者提供重要的诊断和预后结果。